Read your blood results through a longevity lens
Result flagged: No abnormality detected.
Result: Above research-optimal. Context and evidence below.
Meta-analyses including the JUPITER and FOURIER trials suggest cardiovascular event rates continue to fall at LDL levels below 70 mg/dL. This does not mean you have disease — it means the research evidence for additional benefit at lower levels is substantial. Certainty of evidence: High (Cochrane Grade A).
"Normal" means
no disease detected.
It doesn't mean optimal.
Standard reference ranges are designed to catch pathology in a clinical setting. They answer one question: does this patient need treatment today?
Longevity and cardiovascular research asks a harder question: where should biomarkers sit to minimize risk over decades? The answers are often meaningfully different.
"The absence of disease and the presence of health are not the same thing."
BioHelm shows you both thresholds side by side — the lab's cutoff and the research target — along with the evidence quality behind each.
The markers standard panels overlook
Most annual blood panels test for LDL cholesterol — a weak predictor of cardiovascular events. BioHelm prioritizes the markers that cardiovascular and longevity research has identified as far more predictive.
Each biomarker in BioHelm comes with a plain-language explanation, the relevant research target, and an honest statement of evidence quality.
On uncertainty
Not all research targets have the same quality of evidence. BioHelm labels each one with a certainty grade — from Grade A (multiple large RCTs) to Grade C (expert consensus, limited trial data). We won't pretend the evidence is stronger than it is.
Apolipoprotein B — the number of atherogenic particles. More predictive of MACE risk than LDL cholesterol. Target: <70 mg/dL (high risk) or <80 mg/dL (moderate risk).
Lipoprotein(a) — a genetically determined independent cardiovascular risk factor. The European Atherosclerosis Society recommends testing once in a lifetime. Target: <30 nmol/L.
High-sensitivity C-reactive protein — an inflammatory marker. The JUPITER trial demonstrated that elevated hsCRP with normal LDL still predicts cardiovascular events. Target: <1.0 mg/L.
Homeostatic model assessment of insulin resistance — calculated from fasting glucose and insulin. A more sensitive early signal of metabolic dysfunction than HbA1c alone. Target: <1.5.
Gamma-glutamyl transferase — an early marker for oxidative stress and liver metabolic function, predictive of all-cause mortality in several cohort studies. Target: <25 U/L (men), <18 U/L (women).
Bring your results.
Get research context,
not a diagnosis.
Upload or enter the values from any blood panel — private lab, HMO, employer screening. BioHelm reads the numbers and maps them against cardiovascular and longevity research.
We don't prescribe. We don't diagnose. We interpret your data in the context of the science, and we show you what the research actually says about where you stand.
Enter results from any lab panel
Private labs, NHS bloods, HMO panels, employer screenings. If it's a standard blood test, BioHelm can read it.
Research targets with evidence grades
Every biomarker target is graded by the quality of evidence behind it — from Grade A (large RCTs) to Grade C (expert consensus). No overclaiming.
Track changes over time
Add multiple test dates and see whether your biomarkers are moving toward or away from research-optimal zones. Trends matter more than single readings.
Private by design — your data stays yours
BioHelm does not sell or share your health data. Results can be stored locally or in an encrypted account. No insurance implications.
Not a replacement for your doctor
BioHelm is an educational and interpretive tool. We make it easy to arrive at your next appointment with better questions — not a self-diagnosis.
The research behind every number
"The data from your annual blood test contains far more signal than your doctor has time to discuss."
Your results. More context.
No lab visit required.
BioHelm does not compete with your doctor or your lab. It sits between your results and your understanding of them.
Start with your next blood test
No lab kit required. No subscription needed to try it. Bring your results and see what BioHelm can interpret.
Single Analysis
Understand one blood test
- Upload one full blood panel
- Research targets for all supported markers
- Evidence quality grades
- Plain-language explanations
- Trend tracking across tests
- Priority biomarker alerts
BioHelm Pro
Ongoing health navigation
- Unlimited blood panel analyses
- Trend tracking across multiple tests
- Priority biomarker alerts (when a marker crosses a threshold)
- Full research citation library access
- PDF export with annotations for your doctor
- New biomarker coverage as research evolves
No credit card required to start. Cancel anytime.
Your annual blood test is already
telling you more than you know.
BioHelm is an educational and research interpretation tool. It does not provide medical advice, diagnoses, or treatment recommendations. Always consult a qualified healthcare professional with questions about your health.